| New Meds Set to Reshape US CNS and oncology Markets | Gareth Macdonald | 02/18/20 | National |
| Agile Therapeutics Wins FDA Nod for Twirla Contraceptive Patch | Frank Vinluan | 02/14/20 | New York |
| Bio Roundup: Goodbye Belviq, LogicBio on Hold, Revolution’s IPO & More | Frank Vinluan | 02/14/20 | National |
| Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks | Frank Vinluan | 02/13/20 | National |
| Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer | Frank Vinluan | 02/12/20 | San Francisco |
| Ligand’s Icagen Deal Brings Neuro, CF Assets Plus Partnering Potential | Frank Vinluan | 02/12/20 | San Diego |
| CRISPR, CAR-T, Consolidation: Top Advanced Therapy Milestones of 2019 | Dan Stanton | 02/12/20 | National |
| Two Big Pharma Alliances End in Nixed Deals. Here’s What Happened. | Frank Vinluan | 02/11/20 | National |
| FDA Clinical Hold Stops LogicBio’s Gene Editing Study Before It Starts | Frank Vinluan | 02/10/20 | Boston |
| Wave Life Sciences’ Stumble in Duchenne Leads to 22% Staff Layoff | Frank Vinluan | 02/10/20 | Boston |
| Biohaven Drug Fails Anxiety Study, Data in OCD and More Still to Come | Frank Vinluan | 02/10/20 | New York |
| Eli Lilly, Roche Drugs Fail to Move Needle in Genetically Driven Alzheimer’s | Frank Vinluan | 02/10/20 | National |
| Bio Roundup: POTUS on Prices, a16z’s Fund, Aimmune’s Approval & More | Sarah de Crescenzo | 02/07/20 | National |
| Sonoma Bio Launches With $40M to Take Cell Therapy Beyond Cancer | Frank Vinluan | 02/06/20 | San Francisco |
| Scripps Research’s Calibr to Test “Switchable” CAR-T in Clinical Trial | Sarah de Crescenzo | 02/06/20 | San Diego |
| Early Bird Sale Ending for San Diego’s Xcelerating Life Sciences Conference | Editors | 02/06/20 | National |
| Beam Therapeutics IPO Raises $180M After Nearly Doubling Shares Offered | Sarah de Crescenzo | 02/06/20 | Boston |
| Coda Bio Acquires Drug Candidates to Pair With Engineered Receptors | Sarah de Crescenzo | 02/06/20 | San Francisco |
| Aimmune Gets $200M From Nestlé; Licenses Food Allergy Drug Candidate | Sarah de Crescenzo | 02/05/20 | San Francisco |
| Merck Charts an R&D-Focused Course Starting With a $6.5B Spinoff | Frank Vinluan | 02/05/20 | New York |
| Titan Medical’s Cash Crunch Stalls Plans to Get Surgical Robot to FDA | Frank Vinluan | 02/04/20 | National |
| Verily, Santen See Ophthalmology Opportunity Via New Joint Venture | Sarah de Crescenzo | 02/04/20 | San Francisco |
| $750M Fund Looks to Software Sector to Drive Future of Biotech | Sarah de Crescenzo | 02/04/20 | National |
| Bristol-Myers, BioMotiv Pact Leads to a New Fibrosis-Focused Startup | Frank Vinluan | 02/04/20 | New York |
| Passage Bio Plans IPO as Three Gene Therapies Approach the Clinic | Sarah de Crescenzo | 02/03/20 | New York |
| Insmed Drug for Rare Pulmonary Disorder Meets Phase 2 Goals | Sarah de Crescenzo | 02/03/20 | New York |
| United Therapeutics Drug Flunks Small Cell Lung Cancer Clinical Trial | Frank Vinluan | 02/03/20 | National |
| Discovery Labs Converts ex-GSK King of Prussia Site into R&D “Colony” | Dan Stanton | 02/03/20 | New York |
| Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy | Frank Vinluan | 01/31/20 | San Francisco |
| Arcutis Bio Raises $159M in Upsized IPO to Test Skin Disease Drugs | Sarah de Crescenzo | 01/31/20 | San Diego |
